Merck's Keytruda combo misses overall survival in Phase 3 trial in ovarian cancer
Merck said a Keytruda regimen hit the primary endpoint of progression-free survival in a Phase 3 study that enrolled certain patients with ovarian cancer, but …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
